New insight into the molecular basis of hemophilia A

International Journal of Hematology

Volumn 83, Issue 2, 2006, Pages 96-102

  Oldenburg, Johannes ^a   El Maarri, Osman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Expression; Factor VIII; Hemophilia A; mRNA; Mutations

Indexed keywords

BLOOD CLOTTING FACTOR 8; MESSENGER RNA;

EXON; F8 GENE; GENE; GENE DELETION; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; HEMOPHILIA A; HUMAN; INTRON; INVERTED REPEAT; POINT MUTATION; REVIEW; GENETICS; MUTATION; RNA STABILITY;

FACTOR VIII; HEMOPHILIA A; HUMANS; MUTATION; RNA STABILITY;

EID: 33646839304     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06012     Document Type: Review

References (38)

1. McGlynn LK, Mueller CR, Begbie M, Notley CR, Lillicrap D. Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene. Mol Cell Biol. 1996;16:1936-1945.
2. Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J Biol Chem. 1997;272:4327-4334.
3. Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998;273:8537-8544.
4. Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell. 1998;93:61-70.
5. Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet. 2003;34:220-225.
6. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74;1591-1599.
7. Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C. Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease. Br J Haematol. 1991;78:506-514.
8. Hilbert L, d'Oiron R, Fressinaud E, Meyer D, Mazurier C, and the INSERM Network on Molecular Abnormalities in von Willebrand Disease. First identification and expression of a type 2N von Wille-brand disease mutation (E1078K) located in exon 25 of von Wille-brand factor gene. J Thromb Haemost. 2004;2:2271-2273.
9. Schneppenheim R, Lenk H, Obser T, et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost. 2004;92:36-41.
10. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
11. Naylor JA, Buck D, Green P, Williamson H, Bentley D, Giannelli F. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions. Hum Mol Genet. 1995;4:1217-1224.
12. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86:2206-2212.
13. Levinson B, Kenwrick S, Lakich D, Hammonds G Jr, Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics. 1990;7:1-11.
14. Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics. 1992;14:585-589.
15. Kemball-Cook G, Tuddenham EG, Wacey AI. The Factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26:216-219.
16. Peters MF, Ross CA. Isolation of a 40-kDa huntingtin-associated protein. J Biol Chem. 2001;276:3188-3194.
17. Hollestelle MJ, Thinnes T, Crain K, et al. Tissue distribution of factor VIII gene expression in vivo: a closer look. Thromb Haemost. 2001;86:855-861.
18. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
19. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263:6352-6362.
20. Rehemtulla A, Kaufman RJ. Protein processing within the secretory pathway. Curr Opin Biotechnol. 1992;3:560-565.
21. Precup JW, Kline BC, Pass DN. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood. 1991;77:1929-1936.
22. Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb. 1989;9:233-259.
23. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512.
24. O'Brien DP, Johnson D, Byfield P, Tuddenham EG. Inactivation of factor VIII by factor IXa. Biochemistry. 1992;31:2805-2812.
25. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991;266:20139-20145.
26. Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10:133-139.
27. El-Maarri O, Olek A, Balaban B, et al. Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution. Am J Hum Genet. 1998;63:1001-1008.
28. Millar DS, Krawczak M, Cooper DN. Variation of site-specific methylation patterns in the factor VIII (FSC) gene in human sperm DNA. Hum Genet. 1998;103:228-233.
29. Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost. 2004;2:1564-1572.
30. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262:8443-8446.
31. El-Maarri O, Herbiniaux U, Graw J, et al. Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene. J Thromb Haemost. 2005;3:332-339.
32. El-Maarri O, Singer H, Klein C, et al. Lack of F8 mRNA: a novel mechanism leading to hemophilia A. Blood. 2005. In press.
33. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8:23-29.
34. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
35. Oldenburg J, Schroder J, Hermann Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41:82-88.
36. Astermark J, Berntorp E, White GC, Kroner BL, and the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267-272.
37. Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E. The Malmö International Brother Study (MIBS): genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90:924-931.
38. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2005. In press.